L-Citrulline Dose Finding Safety Study in MELAS

Completed · Phase 1

Conditions studied: MELAS Syndrome

In brief

The main purpose of this study is to determine the safest maximum dose of an amino acid, citrulline, which will be used as potential treatment for adult patients with a disorder of energy metabolism called Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). Once established, this dose will be used in a future clinical trial.

Key facts

Study ID

NCT03952234

Run by

Baylor College of Medicine

People needed

10

Starts

2021-04-22

Expected to finish

2024-06-01

Last updated by the study team

2024-06-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of MELAS (stroke-like events, seizures, exercise intolerance or muscle weakness).
• Subject must be aged 18 to 65 years.
• The m.3243A>G mutation in the MTTL1 gene.
• Elevated plasma lactate (>2.2 mmol/L) taken at any point in the screening period (6 months prior to screening visit, including and up to the baseline visit).
• Negative urine pregnancy test, if applicable.
• Score of 26 or higher on the Montreal Cognitive Assessment (MOCA). -

You may not qualify if…

• Evidence of acute illness or physical disability that may interfere with their ability to undergo the study.
• Tobacco use
• Orthostatic hypotension defined as a decrease in systolic blood pressure of 20 mm Hg, or a decrease in diastolic blood pressure of 10 mm Hg, between one and three minutes of standing when compared with blood pressure from the sitting or supine position at the baseline visit.
• Presence of the following signs or symptoms in the past 12 months at grade 3 or higher based on the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: hypotension, syncope, dizziness, blurred vision, fatigue, concentration impairment, nausea, vomiting, diarrhea, hypoglycemia, or headache.
• > 2 seizures in week prior to baseline visit.
• Hypotension defined as systolic blood pressure ≤ 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg at the baseline visit.
• Arginine supplementation within one week prior to baseline visit.
• Inability to travel to the study site.
• Subjects with no evidence of neurological disease, muscle weakness, or exercise intolerance.
• Subjects with evidence of moderate to severe renal impairment ( eGFR < 60 mL/min/1.73 m2 ) at the baseline visit.
• Subjects with poor cognitive ability to provide consent and to understand and report hypoglycemia.
• Unwillingness of sexually active female subjects of childbearing age to practice reliable methods of contraception.
• Intake of drugs that increase NO synthesis, vasodilators, or amino acid supplements that cannot be stopped during the study period.
• Positive urine pregnancy test.
• Score of less than 26 on the Montreal Cognitive Assessment (MOCA). -

Where it is running

• Baylor St. Luke'S Medical Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.